Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AGER | Q15109 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MYC | P01106 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037820 | 1.00 | KDM4E (0.61) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL1737254 | 0.90 | BRD4 (0.61) | ALDH1A1L3MBTL1TSHRBRD4HTT | |
| SCHEMBL29870373 | 0.90 | BRD4 (0.61) | ALDH1A1L3MBTL1TSHRBRD4HTT | |
| SCHEMBL16790442 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL7356194 | 0.87 | ALDH1A1 (0.61) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL14398958 | 0.85 | HTT (0.59) | ALDH1A1L3MBTL1TSHRCYP3A4NPSR1 | |
| SCHEMBL12158504 | 0.84 | BRD4 (0.56) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL6915977 | 0.83 | TSHR (0.57) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL18043964 | 0.83 | BRD4 (0.57) | KDM4EALDH1A1ALOX15L3MBTL1TSHR | |
| SCHEMBL108857 | 0.81 | BRD4 (0.63) | KDM4EL3MBTL1TSHRCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384714-A | The recovery method and production method of substituted or unsubstituted 2,3- pyridinedicarboxylic acid | 北京颖泰嘉和生物科技股份有限公司 | 2019-02-26 | — | — | CN | claimed |
| CN-102584698-B | 2-substutied-3-quinolinic acid ethyl ester compound, preparation method and applications thereof | UNIV SOUTH CHINA NORMAL | 2013-10-09 | — | — | CN | claimed |
| CN-102584698-A | 2-substutied-3-quinolinic acid ethyl ester compound, preparation method and applications thereof | UNIV SOUTH CHINA NORMAL | 2012-07-18 | — | — | CN | claimed |
| CN-118666743-A | Norfloxacin is refined by the method of (2) | 浙江本立科技股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-109384714-A | The recovery method and production method of substituted or unsubstituted 2,3- pyridinedicarboxylic acid | 北京颖泰嘉和生物科技股份有限公司 | 2019-02-26 | — | — | CN | disclosed |
| EP-1858854-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007117180-A1 | AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE' LTD. (RU) | 2007-10-18 | — | — | WO | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | ABBOTT GMBH & CO. KG (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6630493-B1 | Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| EP-0267794-B1 | PROCESS FOR PREPARING POLYOLEFINS | Nippon Petrochemicals Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097508-A1 | Novel heterocyclically substituted amides, their preparation and use | CAPN1, CAPNS1, CAPN2 | KDM4E 2900/4885ALDH1A1 3161/4885ALOX15 3559/4885 |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | KDM4E 702/4885ALDH1A1 656/4885ALOX15 3964/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | KDM4E 4108/4885ALDH1A1 1875/4885ALOX15 1950/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | KDM4E 965/4885ALDH1A1 2246/4885ALOX15 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.